The APAF1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from Jurkat human T-lymphocyte cells, with targeted disruption of the APAF1 gene. This loss-of-function model facilitates investigation of the intrinsic apoptosis pathway in a well-characterized T-cell line. The polyclonal pool contains a heterogeneous mix of APAF1-disrupted alleles, avoiding clonal biases and providing a robust system for apoptotic studies.
Jurkat cells, established from a patient with T-cell acute lymphoblastic leukemia (T-ALL), are an immortalized T lymphocyte line widely used to study T-cell signaling and programmed cell death. They exhibit key T-cell features, including CD3 and CD4 expression, and respond robustly to various apoptotic stimuli. The APAF1 knockout in this background allows specific dissection of the mitochondrial apoptosis branch.
APAF1 (apoptotic protease-activating factor-1) is the central adaptor for intrinsic apoptosis. Upon cytochrome c release from mitochondria, APAF1 assembles the apoptosome, a heptameric complex that recruits and activates caspase-9. Active caspase-9 then cleaves effector caspases-3 and -7, executing cell death. Upstream, p53 and Bcl-2 family proteins like BAX regulate mitochondrial permeabilization. APAF1 activity is modulated by interactions with HSP70 (apoptosome inhibition) and XIAP (caspase inhibition). Thus, APAF1 integrates death signals to trigger the caspase cascade.
In Jurkat T cells, APAF1 knockout impairs apoptosome formation and attenuates caspase activation in response to intrinsic apoptotic triggers such as DNA damage or chemotherapeutics. This model helps elucidate APAF1-dependent versus -independent death pathways and is relevant for understanding apoptosis resistance in T-cell malignancies. The polyclonal nature ensures population-level phenotypes.
Applications include mechanistic studies of intrinsic apoptosis, screening for compounds that bypass APAF1-mediated death, and testing anticancer agents targeting mitochondria. Suitable assays include Western blotting for caspase activation, cytochrome c release assays, Annexin V/PI flow cytometry, caspase-3/7 activity measurements, and cell viability assays (MTT/ATP). Researchers can model chemotherapy resistance in T-ALL and evaluate pro-apoptotic compounds. For further details, contact Ascent Research.
